Business Context and Reporting Period
This Form 8-K was filed on August 10, 2023, by Blue Water Biotech, Inc. The request identifies Onconetix, Inc., but the filing text names Blue Water Biotech, Inc. as the registrant. The filing reports an event under Item 8.01 and does not present quarterly or annual financial results.
Key Financial Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics.
Material Event and Changes
On August 10, 2023, the company announced an agreement with Copay Consultants, LLC to build copay assistance programs for its commercial products, including ENTADFI® and ZONTIVITY®.
The filing does not disclose the agreement’s financial terms, duration, costs, expected revenue impact, or comparison with the prior period.
Outlook, Risks, and Unusual Items
No formal financial guidance or outlook is provided. The filing does not describe material risks, contingencies, contractual obligations, or unusual charges associated with the agreement. The related press release is filed as Exhibit 99.1 and incorporated by reference.
Investor Verification Items
- Verify the registrant identity, because the supplied request names Onconetix, Inc., while the filing names Blue Water Biotech, Inc.
- Review Exhibit 99.1 for the agreement’s commercial, operational, and financial terms.
- Determine whether the copay assistance programs could affect product demand, net pricing, reimbursement, selling expenses, or cash flow.
- Confirm the regulatory and commercial status of ENTADFI and ZONTIVITY and any related launch or distribution obligations.